David Shaw’s Madrigal Pharmaceuticals MDGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $18.8M | Buy |
35,071
+4,932
| +16% | +$2.53M | 0.01% | 1322 |
|
|
2026
Q1 | $15.8M | Sell |
30,139
-58,415
| -66% | -$27.9M | 0.01% | 1303 |
|
|
2025
Q4 | $51.6M | Sell |
88,554
-7,628
| -8% | -$3.9M | 0.03% | 681 |
|
|
2025
Q3 | $44.1M | Sell |
96,182
-15,799
| -14% | -$5.89M | 0.02% | 720 |
|
|
2025
Q2 | $33.9M | Buy |
111,981
+12,975
| +13% | +$3.87M | 0.02% | 752 |
|
|
2025
Q1 | $32.8M | Buy |
99,006
+75,162
| +315% | +$24.7M | 0.03% | 667 |
|
|
2024
Q4 | $7.36M | Buy |
+23,844
| New | +$6.71M | 0.01% | 1702 |
|
|
2024
Q3 | – | Sell |
-947
| Closed | -$242K | – | 4746 |
|
|
2024
Q2 | $265K | Sell |
947
-5,114
| -84% | -$1.22M | ﹤0.01% | 3958 |
|
|
2024
Q1 | $1.62M | Sell |
6,061
-9,561
| -61% | -$2.25M | ﹤0.01% | 2781 |
|
|
2023
Q4 | $3.61M | Buy |
15,622
+9,708
| +164% | +$1.7M | ﹤0.01% | 2181 |
|
|
2023
Q3 | $864K | Buy |
5,914
+316
| +6% | +$59.5K | ﹤0.01% | 3148 |
|
|
2023
Q2 | $1.29M | Sell |
5,598
-19,340
| -78% | -$5.24M | ﹤0.01% | 2927 |
|
|
2023
Q1 | $6.04M | Sell |
24,938
-128,500
| -84% | -$35M | 0.01% | 1778 |
|
|
2022
Q4 | $44.5M | Buy |
153,438
+130,458
| +568% | +$12.8M | 0.05% | 481 |
|
|
2022
Q3 | $1.49M | Buy |
22,980
+799
| +4% | +$55.5K | ﹤0.01% | 3261 |
|
|
2022
Q2 | $1.59M | Sell |
22,181
-585
| -3% | -$43K | ﹤0.01% | 3271 |
|
|
2022
Q1 | $2.23M | Sell |
22,766
-9,726
| -30% | -$820K | ﹤0.01% | 3188 |
|
|
2021
Q4 | $2.75M | Sell |
32,492
-5,732
| -15% | -$471K | ﹤0.01% | 3053 |
|
|
2021
Q3 | $3.05M | Buy |
38,224
+16,812
| +79% | +$1.45M | ﹤0.01% | 2611 |
|
|
2021
Q2 | $2.09M | Buy |
21,412
+13,694
| +177% | +$1.62M | ﹤0.01% | 2900 |
|
|
2021
Q1 | $903K | Buy |
7,718
+3,901
| +102% | +$455K | ﹤0.01% | 3194 |
|
|
2020
Q4 | $424K | Buy |
+3,817
| New | +$467K | ﹤0.01% | 3462 |
|
|
2019
Q4 | – | Sell |
-2,868
| Closed | -$278K | – | 4085 |
|
|
2019
Q3 | $247K | Sell |
2,868
-5,759
| -67% | -$540K | ﹤0.01% | 3544 |
|
|
2019
Q2 | $904K | Buy |
8,627
+5,747
| +200% | +$616K | ﹤0.01% | 2732 |
|
|
2019
Q1 | $361K | Buy |
+2,880
| New | +$358K | ﹤0.01% | 3140 |
|
|
2018
Q3 | – | Sell |
-1,200
| Closed | -$301K | – | 3867 |
|
|
2018
Q2 | $336K | Sell |
1,200
-41,411
| -97% | -$7.27M | ﹤0.01% | 3322 |
|
|
2018
Q1 | $4.98M | Buy |
42,611
+17,619
| +70% | +$2.17M | 0.01% | 1402 |
|
|
2017
Q4 | $2.29M | Buy |
+24,992
| New | +$1.43M | ﹤0.01% | 2045 |
|
|
2016
Q3 | – | Sell |
-7,025
| Closed | -$64K | – | 3471 |
|
|
2016
Q2 | $64K | Sell |
7,025
-6,020
| -46% | -$72.2K | ﹤0.01% | 3280 |
|
|
2016
Q1 | $110K | Sell |
13,045
-9,934
| -43% | -$83K | ﹤0.01% | 3275 |
|
|
2015
Q4 | $283K | Buy |
22,979
+14,853
| +183% | +$408K | ﹤0.01% | 3400 |
|
|
2015
Q3 | $495K | Sell |
8,126
-3,931
| -33% | -$284K | ﹤0.01% | 3065 |
|
|
2015
Q2 | $941K | Buy |
12,057
+6,623
| +122% | +$556K | ﹤0.01% | 2755 |
|
|
2015
Q1 | $369K | Sell |
5,434
-4,780
| -47% | -$410K | ﹤0.01% | 3218 |
|
|
2014
Q4 | $947K | Sell |
10,214
-9,431
| -48% | -$975K | ﹤0.01% | 2866 |
|
|
2014
Q3 | $2.07M | Sell |
19,645
-7,955
| -29% | -$1.11M | ﹤0.01% | 2217 |
|
|
2014
Q2 | $3.95M | Buy |
+27,600
| New | +$4.03M | 0.01% | 1790 |
|
|
2014
Q1 | – | Sell |
-6,878
| Closed | -$1.26M | – | 4475 |
|
|
2013
Q4 | $1.26M | Sell |
6,878
-1,268
| -16% | -$232K | ﹤0.01% | 2960 |
|
|
2013
Q3 | $1.8M | Buy |
8,146
+6,455
| +382% | +$1.37M | ﹤0.01% | 2521 |
|
|
2013
Q2 | $295K | Buy |
+1,691
| New | +$441K | ﹤0.01% | 3582 |
|
Other funds holding MDGL
BBA
RI
JT
ACA
PC
David Shaw's MDGL Position: Q2 2026 in Review
David Shaw increased its Madrigal Pharmaceuticals (MDGL) stake by 16% in Q2 2026, buying an estimated $2.53M and bringing the position to 35,071 shares worth $18.8M. The position accounts for 0.01% of the portfolio, ranked #1322.
David Shaw first reported a position in MDGL in Q2 2013 and has held it in 40 quarters since. The position peaked at $51.6M in Q4 2025. 411 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.
- David Shaw held 35,071 shares of Madrigal Pharmaceuticals worth $18.8M as of Q2 2026.
- David Shaw bought 4,932 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $2.53M.
- Madrigal Pharmaceuticals made up 0.01% of David Shaw's portfolio in Q2 2026, its #1322 holding.
- David Shaw first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 40 quarters since.
- David Shaw's Madrigal Pharmaceuticals position peaked at $51.6M in Q4 2025.
- 411 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.
Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.